Updated: Minute Insight: FDA Clears Zimmer Biomet’s Identity Shoulder, ZB Calls It ‘Biggest Shoulder Launch In the Last Five Years’

Zimmer Biomet said on 20 September that the FDA cleared its Identity shoulder system and expects it to be available to US surgeons in the fourth quarter.  

Minute Insight
• Source: Informa/Alamy

[Editor's Note: This article was updated on 20 September to include the expected launch of the Identity shoulder system to US surgeons in the fourth quarter, and provide more information on the system from Zimmer Biomet.]

Zimmer Biomet Holdings, Inc.’s Identity shoulder replacement implant received 510(k) clearance from the US Food and Drug Administration on 15 September. The new system is expected to be...

More from Minute Insights

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.